RIO DE JANEIRO, BRAZIL - Biomm pharmaceutical company announced it has been authorized by the Brazilian Health Regulatory Agency (ANVISA) to begin phase 3 clinical trials in Brazil of the drug leronlimab, to be used against Covid-19.
The goal of the drug is to prevent the disease from evolving into a more severe condition that requires invasive mechanical ventilation.
Leronlimab is a biological drug and acts to prevent an excessive response from the immune system of patients infected with the novel coronavirus, thereby reducing the overproduction of inflammatory cytokines, also known as "cytokine storm."
According to the drugmaker, this inflammatory . . .